Pleiotropic prodrugs: Design of a dual butyrylcholinesterase inhibitor and 5-HT
Alzheimer Disease
/ drug therapy
Animals
Butyrylcholinesterase
/ metabolism
Cholinesterase Inhibitors
/ chemical synthesis
Dose-Response Relationship, Drug
Drug Design
Electrophorus
Humans
Locomotion
/ drug effects
Male
Mice
Models, Molecular
Molecular Structure
Prodrugs
/ chemical synthesis
Receptors, Serotonin
/ metabolism
Structure-Activity Relationship
5-HT(6) receptors
Alzheimer’s disease
Butyrylcholinesterase
MTDL
Prodrugs
Journal
European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510
Informations de publication
Date de publication:
15 Jan 2021
15 Jan 2021
Historique:
received:
24
08
2020
revised:
23
10
2020
accepted:
24
11
2020
pubmed:
15
12
2020
medline:
23
4
2021
entrez:
14
12
2020
Statut:
ppublish
Résumé
Beside acetylcholinesterase, butyrylcholinesterase could be considered as a putative target of interest for the symptomatic treatment of Alzheimer's disease (AD). As a result of complexity of AD, no molecule has been approved since 2002. Idalopirdine, a 5-HT
Identifiants
pubmed: 33310288
pii: S0223-5234(20)31031-X
doi: 10.1016/j.ejmech.2020.113059
pii:
doi:
Substances chimiques
Cholinesterase Inhibitors
0
Prodrugs
0
Receptors, Serotonin
0
serotonin 6 receptor
0
Butyrylcholinesterase
EC 3.1.1.8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
113059Informations de copyright
Copyright © 2020 Elsevier Masson SAS. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.